Related Experiment Video
Updated: Aug 7, 2026
08:57
Identifying, Diagnosing, and Grading Malignant Peripheral Nerve Sheath Tumors in Genetically Engineered Mouse Models
Published on: May 17, 2024
[Markers of malignancy in pheochromocytomas]
Stanisław Sporny1, Jacek Musiał
1Medical University of Lodz, Poland.
Endokrynologia Polska
|July 6, 2006
Summary
Pheochromocytomas are tumors that can cause hypertension. Identifying malignancy markers like high telomerase expression and proliferative activity is crucial for effective treatment before metastasis.
Area of Science:
- Endocrinology
- Oncology
- Pathology
Background:
- Pheochromocytomas are catecholamine-releasing neoplasms causing hypertension, curable by surgical excision.
- Tumor aggressiveness is primarily determined by metastasis, necessitating early malignancy markers.
- Current research focuses on identifying biological markers for early detection of malignant pheochromocytomas.
Purpose of the Study:
- To investigate potential biological markers for assessing pheochromocytoma aggressiveness.
- To identify indicators of malignancy that precede metastasis.
Main Methods:
- Analysis of microscopic features, immunohistochemical markers, and molecular disorders.
- Evaluation of the Pheochromocytoma of the Adrenal gland Scaled Score (PASS) scale.
- Immunohistochemical detection of telomerase, hTERT, and MIB-1 (proliferative activity).
Main Results:
- The PASS scale is considered a significant factor in estimating pheochromocytoma aggressiveness.
- High expression of telomerase and hTERT supports biological malignancy.
- High proliferative activity, measured by MIB-1 immunohistochemistry, strongly indicates malignancy.
Conclusions:
- Early identification of malignant pheochromocytomas is essential for targeted therapy.
- Telomerase, hTERT expression, and proliferative activity are strong indicators of pheochromocytoma malignancy.
- Further research into these markers can improve therapeutic strategies and patient outcomes.